John Bellano

John Bellano's Title

John Bellano holds the title of Chief Commercial Officer (CCO) at Sterilis Solutions. With a strategic vision and a wealth of experience in the commercial sector, John has been instrumental in driving the company’s growth and expanding its market presence. His role involves overseeing the commercialization strategy, enhancing sales operations, and fostering partnerships to ensure the company’s products reach their target markets effectively.

John Bellano's Background

John Bellano began his illustrious career in the pharmaceuticals industry, where he developed a strong foundation in commercial operations. He later transitioned to the field of molecular diagnostics, where he has dedicated the past 20 years of his career. This transition highlights his adaptability and commitment to advancing healthcare through innovative diagnostic solutions. His extensive background in both pharmaceuticals and molecular diagnostics positions him as a thought leader in the industry.

John Bellano's Achievements

One of John Bellano's most notable achievements was his tenure at Assurex Health, which is part of Myriad Genetics. During his five-year span with the organization, he played a pivotal role in growing the company’s revenue from $700,000 to a remarkable run rate of $100 million. This exponential growth under his leadership underscores his strategic acumen and ability to drive significant commercial success. His achievements have set a benchmark in the pharmacogenomics industry, showcasing his expertise in scaling businesses and maximizing revenue potential.

John Bellano's Experience

In his extensive career, John Bellano has held key commercial leadership roles at prominent pharmacogenomic companies such as Assurex Health and AltheaDx. His experience at these companies involved leading commercial strategy, optimizing sales processes, and driving market adoption of complex diagnostic solutions. At Sterilis Solutions, he continues to leverage his deep industry knowledge and commercial expertise to propel the company forward. His decades-long experience in the molecular diagnostics space has equipped him with unique insights into market dynamics and customer needs.